ACAD vs VRTX: fair value comparison
Acadia Pharmaceuticals Inc. and Vertex Pharmaceuticals Incorporated · Updated 2026-10-19
ACAD currently screens as overvalued while VRTX screens as fairly valued. Within Healthcare, VRTX currently sits closer to the top of our ranking by discount to fair value.
| ACAD | VRTX | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $19.12 | $510.08 |
| 12-month range | $18.62–$30.57 | $409.47–$557.96 |
| Rank by discount to fair value | #74 of 108 Healthcare | #70 of 108 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | Strong |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: ACAD fair value analysis · VRTX fair value analysis